Emmessar Biotech & Nutrition Ltd.

As of June 30, 2026, Emmessar Biotech & Nutrition Ltd. carries a market capitalization of 123.40M, placing it among publicly traded companies globally. Its enterprise value stands at 123.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Emmessar Biotech & Nutrition Ltd. has 5.00M shares outstanding.

As of June 30, 2026, Emmessar Biotech & Nutrition Ltd. trades at a trailing price-to-earnings ratio of 31.29.

These figures are as of June 30, 2026. The EV/Sales ratio of 36.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 123.40M versus a market cap of 123.40M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 198,352.94 in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Emmessar Biotech & Nutrition Ltd. recorded 1.15M in income tax expense. That works out to an effective tax rate of 22.51, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.11M, leaving 3.96M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Emmessar Biotech & Nutrition Ltd.'s stock has declined approximately 27.77% over the past 52 weeks. The 50-day moving average sits at 23.64, while the 200-day moving average is 25.43.

Over the twelve months ended June 30, 2026, Emmessar Biotech & Nutrition Ltd. generated 3.37M in revenue and converted that into 3.96M in net income, yielding earnings per share of 0.79. EBITDA reached -14.29M, while operating income came in at -15.27M.

Over the twelve months ended June 30, 2026, Emmessar Biotech & Nutrition Ltd. posted a gross margin of 67.35, reflecting its pricing power and cost economics. The operating margin of -453.00 and net profit margin of 117.47 provide insight into operational efficiency.